Soleo Health adds 4th drug from Alnylam Pharmaceuticals
By HME News Staff
Updated 9:54 AM CDT, Tue October 4, 2022
FRISCO, Texas – Soleo Health has added AMVUTTRA (vutrisiran) to its specialty pharmacy portfolio to treat adults with the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. Soleo Health offers newly FDA-approved AMVUTTRA injections to patients in their homes (after an evaluation and recommendation by the treating physician) or at one of its ambulatory infusion centers (AICs) nationwide. “This marks the fourth therapy Soleo Health now offers from Alnylam Pharmaceuticals’ rare disease product portfolio, further strengthening our ability to care for more patients living with rare disease who benefit from innovative new therapies like AMVUTTRA,” said Drew Walk, Soleo Health CEO. Soleo Health employs specially trained interdisciplinary teams comprised of highly experienced pharmacists, registered nurses, reimbursement specialists and patient care ambassadors – each of whom is trained on the clinical profile and administration for AMVUTTRA. The company has 21 pharmacy locations with national nursing coverage and pharmacy licensure in 50 states, and is accredited by URAC, ACHC (with Distinction in Rare Disease and Orphan Drugs) and The Joint Commission. Additionally, the company operates more than 40 infusion centers throughout the U.S.
Comments